YOLFTbeta
Iconovo

Iconovo

ICO · ST · Healthcare / Medical Devices

1.05SEK+0.00 (+0.48%)

Price History

Full chart

Market Stats

Previous Close1.04
Open1.08
Day Range1.05 – 1.10
52-Week Range0.87 – 2.25
Volume18.18K
Market Cap120.21M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.40
Dividend Yield0.00%
Beta0.42
50-Day Avg1.17
200-Day Avg1.15

About

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Anders Mansson
  • Employees12
  • HeadquartersIdeongatan 3 A-B, Lund, Sweden, 223 70, Sweden
  • Websitehttps://www.iconovo.se

Leadership

  • Mr. Anders ManssonChief Executive Officer · b. 1967
  • Dr. Orest LastowCo-Founder, Senior Scientific Advisor & Director · b. 1964
  • Mr. Henrik Damkjaer Simonsen M.Sc.Chief Financial Officer · b. 1963
  • Dr. Mikael ArinderHead of Science & Technology · b. 1964
  • Ms. Lotta AskerlundHR Manager · b. 1973
  • Mr. Carl ForslundHead of Industrial Design
  • Ms. Vesna ÅkerbergHead of Novel & Reformulation Development
  • Ms. Maria EkbladHead of Generics Development
  • Madeleine HillerBusiness Controller

Financials

Income Statement

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue149.70K14.38M20.07M11.91M11.74M17.79M15.41M17.12M7.08M2.93M1.10M
Growth (%)-+9504.07%+39.61%-40.67%-1.43%+51.58%-13.39%+11.08%-58.65%-58.55%-62.34%
Cost of Revenue1.21M-2.02M-615.00K37.17K-4.36M-3.02M-5.90M-128.34K-10.50M-16.20M44.86M
Gross Profit-1.06M16.40M20.69M11.87M16.09M20.81M21.31M17.24M17.58M19.13M-43.75M
Gross Margin-707.53%114.08%103.06%99.69%137.13%116.96%138.27%100.75%248.33%652.11%-3959.55%
Operating Expense212.79M17.95M17.69M27.87M37.30M47.80M65.60M63.35M60.21M0
Operating Income-1.06M3.61M2.74M-5.82M-11.77M-16.49M-26.50M-48.36M-45.78M-41.08M-43.75M
Operating Margin-707.54%25.08%13.66%-48.87%-100.32%-92.69%-171.96%-282.53%-646.72%-1400.00%-3959.55%
EBITDA-876.99K4.12M2.83M-3.75M-11.08M-16.62M-24.90M-38.73M-35.29M-29.83M-34.05M
EBITDA Margin-585.84%28.68%14.09%-31.46%-94.38%-93.42%-161.61%-226.28%-498.61%-1016.56%-3081.63%
Net Income-897.38K2.46M1.45M-4.29M-11.01M-17.13M-26.16M-50.31M-45.89M-41.14M-43.36M
Net Income Margin-599.46%17.12%7.24%-36.06%-93.77%-96.30%-169.77%-293.93%-648.37%-1402.18%-3924.34%
R&D--1.13M1.24M2.27M3.49M4.09M4.93M4.88M4.72M-
R&D as % of Total Revenue--5.62%10.40%19.32%19.60%26.57%28.82%68.98%160.73%-
Interest Expense359100.00K64.21K5.15K1.30K300360.01K302.48K511.57K550.00K449.00K
Interest Expense % of Total Revenue0.24%0.70%0.32%0.04%0.01%0.00%2.34%1.77%7.23%18.75%40.63%

Balance Sheet

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.47M20.11M42.10M72.70M113.75M101.04M148.54M121.27M128.08M145.69M131.08M
Total Liabilities5.20M11.38M10.57M8.72M4.96M8.32M11.51M31.97M14.55M16.47M13.16M
Total Equity6.27M8.73M31.52M63.99M108.79M92.73M137.03M89.29M113.53M129.21M117.92M
Cash5.12M11.54M22.48M53.05M89.16M61.69M94.94M13.45M18.48M24.69M6.56M
Total Debt-2.00M-----10.03M7.72M7.90M4.97M
Net Debt-5.12M-9.54M-22.48M-53.05M-89.16M-61.69M-94.94M-3.42M-10.76M-16.78M-1.59M

Cash Flow

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.02M-3.82M-1.02M-12.08M-15.96M-11.01M-43.70M-38.60M-24.54M-31.87M
Investing Cash Flow-1.60M-4.58M-5.17M-8.01M-12.58M-25.99M-36.95M-22.91M-21.90M-14.09M
Financing Cash Flow2.00M19.34M36.76M56.20M1.07M70.25M-936.22K66.55M52.65M27.83M
Capital Expenditure1.60M4.59M5.17M8.01M12.58M25.89M36.95M22.91M21.90M31.87M
Free Cash Flow4.42M-8.40M-6.18M-20.09M-28.54M-36.91M-80.65M-61.43M-46.44M-45.96M
FCF to OCF73.37%220.15%608.30%166.29%178.80%335.12%184.55%159.14%189.25%144.21%

Earnings

Report DateAug 31, 2018Nov 9, 2018Feb 14, 2019Apr 25, 2019Aug 16, 2019Oct 25, 2019Feb 14, 2020May 8, 2020Aug 19, 2020Oct 27, 2020Feb 17, 2021Apr 29, 2021Aug 20, 2021Oct 28, 2021Feb 18, 2022Apr 29, 2022Jul 15, 2022Oct 28, 2022Feb 8, 2023Apr 28, 2023Jul 14, 2023Oct 27, 2023Feb 15, 2024Apr 25, 2024Jul 12, 2024Oct 24, 2024Feb 28, 2025Apr 24, 2025Jul 14, 2025Oct 24, 2025Feb 27, 2026Apr 22, 2026Aug 20, 2026
EPS Estimate-------------------6.61--------------
EPS Actual0.05-0.310.230.07-0.38-0.26-1.10-0.55-0.82-0.25-0.58-0.91-0.86-0.43-0.98-1.05-1.38-1.14-1.88-1.35-1.28-0.97-0.84-0.69-0.60-0.70-0.53-0.53-0.42-0.17-0.24-0.10-0.10
Surprise------------------71.56%--------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap120.21M
Enterprise Value86.93M
Trailing P/E0.00
Forward P/E0.00
Price / Sales69.82
Price / Book0.80
EPS-0.40
Book Value1.55
Revenue (TTM)1.72M
Gross Profit (TTM)-3.40M
EBITDA-37.92M
Profit Margin0.00%
Operating Margin-1737.87%
Return on Equity-27.23%
Return on Assets-15.33%
Shares Outstanding96.17M
Shares Float92.60M
Beta0.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%